Healthcare / Drug Manufacturers - Specialty & GenericBSE
$35.00
-1.61 (-4.40%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 34% · confianza 17%
FCF escenarios
weak_data · normalized FCF $-3.5M · quality 39.7/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
48/100
C
Piotroski
4/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$199M
P/E
47.3x
↑EV/EBITDA
14.4x
↑ROE
4.8%
↑Gross Margin
59.1%
↑Debt/Equity
0.31
↑TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
+0.4%
FCF CAGR
—
FCF margin
-13.9%
FCF / Net income
-1.82x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $62.7M · net income $4.8M · FCF $-8.7M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $62.7M | $62.7M | $60.1M | $61.8M | $61.9M |
| Net Income | $4.8M | $4.8M | $4.3M | $4.1M | $4.8M |
| EBITDA | $12.8M | $12.8M | $13.0M | $13.3M | $11.8M |
| EPS | 1.07 | 1.07 | 0.96 | 0.14 | 1.08 |
| Gross Margin | 59.1% | 59.1% | 58.0% | 55.5% | 57.3% |
| Operating Margin | 13.4% | 13.4% | 14.6% | 15.5% | 13.2% |
| Net Margin | 7.6% | 7.6% | 7.1% | 6.6% | 7.8% |
| Balance Sheet | |||||
| Debt/Equity | 0.31 | 0.31 | 0.30 | 0.46 | 0.47 |
| Current Ratio | 2.49 | 2.49 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $-8.7M | $-8.7M | $14.7M | $-3.5M | $-15.1M |
| Returns | |||||
| ROE | 4.8% | 4.8% | 4.5% | 4.4% | 5.2% |
| Valuation | |||||
| P/E | 47.30 | 47.30 | 7.21 | 38.46 | 3.78 |
| EV/EBITDA | 14.45 | 14.45 | 4.44 | 14.85 | 5.03 |
| P/B | 1.56 | 1.56 | 0.33 | 1.71 | 0.20 |
| Growth & Yield | |||||
| Revenue Growth | 4.4% | 4.4% | -2.8% | -0.1% | — |
| EPS Growth | 11.5% | 11.5% | 612.4% | -87.5% | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
3Y implied EPS CAGR
42.5%
EPS terminal req.
$3.11
Spread vs growth
-31.0%
5Y implied EPS CAGR
28.5%
EPS terminal req.
$3.76
Spread vs growth
-17.0%
10Y implied EPS CAGR
18.9%
EPS terminal req.
$6.05
Spread vs growth
-7.4%
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
-11.7%
Start / end P/E
41.2x → 32.6x
EPS bridge
0.96 → 1.07
Residual
-2.4%
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.